A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Principal Investigator
Thomas Pisansky, MD
Status
Terminated
Date of Study Termination
May 20 2022
Disease Site
Genitourinary [GU]
Prostate
Phase
III
Developmental Therapeutics
No
Primary Objective
The primary endpoint is to compare the efficacy of moderate-duration (28-week) neoadjuvant total androgen suppression and RT with short-duration (8-week) neoadjuvant total androgen suppression and RT as related to disease-specific survival.
Patient Population
Histologically confirmed prostate adenocarcinoma within 180 days of randomization
Zubrod performance score 0-1
Prostatic biopsy tumor grading by the Gleason Score classification
Target Accrual
1540
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.